#Roche

Roche says its investigational breast cancer pill giredestrant could still become a major product, with CEO Thomas Schinecker arguing it may one day outsell Herceptin despite an earlier first-line trial failure.

Data presented at the American Academy of Neurology meeting suggest Roche’s multiple sclerosis pill outperformed Aubagio on relapse timing, while raising monitoring concerns around liver toxicity.

Roche is expanding work with longtime partner C4 Therapeutics in a deal worth $20 million upfront, underscoring rising interest in degrader-antibody conjugates as a new twist on an already hot cancer-drug category.